InvestorsHub Logo
Followers 16
Posts 4819
Boards Moderated 0
Alias Born 04/25/2003

Re: DRG1025 post# 135442

Thursday, 12/30/2021 5:10:21 PM

Thursday, December 30, 2021 5:10:21 PM

Post# of 140474
HERE IT IS:

Titan Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

TMDI
-0.47%

Thu, December 30, 2021, 3:48 PM
In this article:

TORONTO, December 30, 2021--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of an innovative single access robotic-assisted surgery system, today received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days.

These notifications do not impact the company’s listing on the Nasdaq Capital Market at this time. In accordance with Listing Rule 5810(c)(3)(A), the company has a period of 180 calendar days from the date of notification, being until June 28, 2022, to regain compliance with the minimum bid price requirement, during which time the shares will continue to trade on the Nasdaq Capital Market. If at any time before June 28, 2022, the bid price of the shares closes at or above US$1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the company has achieved compliance with the minimum bid price requirement and will consider such deficiency matters closed.

The company is also listed on the Toronto Stock Exchange and the notification letter does not affect the company's compliance status with such listing.

The company intends to evaluate all available options to resolve the deficiency and regain compliance with Nasdaq Rule 5550(a)(2).

We all have a right to post our opinions, whether you agree with them or not.